Clinical Trial Update: Efficacy and Safety of Telbivudine in Patients With Chronic Hepatitis B [Phase 4]

View source ↗

Summary

A Phase 4 trial of telbivudine for chronic hepatitis B has been withdrawn; the document provides no efficacy or safety data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Telbivudine (telbivudine)

Snippet

Sponsor: Novartis | Conditions: Chronic Hepatitis B | Phase 4 | Status: WITHDRAWN